DNLI
Denali Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.17
+8.83%Next report
Analyst consensus
- Next report date
- Feb 25, 2027
- EPS estimate
- -$0.64
- Revenue estimate
- $29.6M
Latest reported
- Last report date
- Nov 3, 2026
- EPS actual
- $0.37
- EPS estimate
- -$0.27
- Revenue actual
- $17.8M
- Revenue estimate
- $12.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +53.0%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $35
- PT range
- $34 – $35
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 3, 2026 | -$0.27 | $0.37 | Beat 236.56% | $17.8M |
| Aug 6, 2026 | -$0.51 | -$0.68 | Miss -32.54% | $3.6M |
| May 7, 2026 | -$0.73 | -$0.69 | Beat 5.48% | — |
| Nov 6, 2025 | -$0.76 | -$0.74 | Beat 2.63% | — |
| Feb 27, 2025 | -$0.75 | -$0.67 | Beat 10.67% | — |
| Nov 6, 2024 | -$0.60 | -$0.63 | Miss -5.00% | — |
| Aug 1, 2024 | -$0.68 | -$0.59 | Beat 13.24% | — |
| Feb 27, 2024 | -$0.82 | -$0.86 | Miss -4.88% | $305.0M |
| Feb 27, 2023 | -$0.78 | -$0.75 | Beat 3.85% | $10.3M |
| Nov 3, 2022 | -$0.83 | -$0.84 | Miss -1.20% | $3.6M |
| May 5, 2022 | -$0.47 | -$0.53 | Miss -12.77% | $42.1M |
| Feb 28, 2022 | -$0.41 | -$0.62 | Miss -51.22% | $12.5M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 25, 2027